Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: Roles of number of drug exposure, drug dose, and test-retest interval

Behavioural Pharmacology

Volumn 23, Issue 4, 2012, Pages 380-391

  Swalve, Natashia ^a   Li, Ming ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

conditioned avoidance response; haloperidol; olanzapine; parameters; rat; sensitization

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; DRUG MECHANISM; DRUG SENSITIZATION; NONHUMAN; PARAMETRIC TEST; PROVOCATION TEST; RAT; TEST RETEST RELIABILITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84863844513     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32835651ea     Document Type: Article

References (62)

1. Amtage J, Schmidt WJ (2003). Context-dependent catalepsy intensification is due to classical conditioning and sensitization. Behav Pharmacol 14: 563-567. (Pubitemid 38293517)
2. Anagnostaras SG, Robinson TE (1996). Sensitization to the psychomotor stimulant effects of amphetamine: modulation by associative learning. Behav Neurosci 110:1397-1414. (Pubitemid 27009202)
3. Antelman SM, Gershon S (1998). Clinical application of time-dependent sensitization to antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry 22:65-78. (Pubitemid 28096429)
4. Antelman SM, Levine J, Gershon S (2000). Time-dependent sensitization: the odyssey of a scientific heresy from the laboratory to the door of the clinic. Mol Psychiatry 5:350-356. (Pubitemid 30455947)
5. Barnes DE, Robinson B, Csernansky JG, Bellows EP (1990). Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants. Pharmacol Biochem Behav 36:883-887. (Pubitemid 20272310)
6. Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, Greengard P (2008). Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11:932-939.
7. Boyda HN, Procyshyn RM, Tse L, Wong D, Pang CC, Honer WG, Barr AM (2012). Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology 62:1391-1400.
8. Carey RJ, DeVeaugh-Geiss J (1984). Treatment schedule as a determinant of the development of tolerance to haloperidol. Psychopharmacology (Berl) 82:164-167. (Pubitemid 14184535)
9. Centonze D, Usiello A, Costa C, Picconi B, Erbs E, Bernardi G, et al. (2004). Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. J Neurosci 24:8214-8222. (Pubitemid 39280800)
10. Csernansky JG, Bellows EP, Barnes DE, Lombrozo L (1990). Sensitization versus tolerance to the dopamine turnover-elevating effects of haloperidol: the effect of regular/intermittent dosing. Psychopharmacology (Berl) 101: 519-524. (Pubitemid 20220045)
11. Domjan M (2005). Pavlovian conditioning: a functional perspective. Annu Rev Psychol 56:179-206. (Pubitemid 40300783)
12. Emmett-Oglesby MW, Goudie AJ (1989). Psychoactive drugs: tolerance and sensitization. Clifton, NJ: Humana Press.
13. Fallon P, Dursun SM (2011). A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol 25:755-762.
14. Goudie AJ, Cole JC, Sumnall HR (2007a). Olanzapine and JL13 induce crosstolerance to the clozapine discriminative stimulus in rats. Behav Pharmacol 18:9-17. (Pubitemid 46103279)
15. Goudie AJ, Cooper GD, Cole JC, Sumnall HR (2007b). Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. J Psychopharmacol 21:179-190. (Pubitemid 46280470)
16. Grande C, Zhu H, Martin AB, Lee M, Ortiz O, Hiroi N, Moratalla R (2004). Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats. Biol Psychiatry 55:457-463. (Pubitemid 38338532)
17. Grignaschi G, Burbassi S, Zennaro E, Bendotti C, Cervo L (2004). A single high dose of cocaine induces behavioural sensitization and modifies mRNA encoding GluR1 and GAP-43 in rats. Eur J Neurosci 20:2833-2837. (Pubitemid 39573800)
18. Kalivas PW, Alesdatter JE (1993). Involvement of N-methyl-D-aspartate receptor stimulation in the ventral tegmental area and amygdala in behavioral sensitization to cocaine. J Pharmacol Exp Ther 267:486-495. (Pubitemid 23325044)
19. Kalivas PW, Stewart J (1991). Dopamine transmission in the initiation and expression of drug-and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 16:223-244.
20. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000). A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559. (Pubitemid 30349435)
21. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631. (Pubitemid 36459179)
22. Kippin TE, Kapur S, van der Kooy D (2005). Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J Neurosci 25:5815-5823. (Pubitemid 40847894)
23. Klein A, Schmidt WJ (2003). Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency. Behav Pharmacol 14:49-53. (Pubitemid 36279025)
24. Kline L, Decena E, Hitzemann R, McCaughran J Jr. (1998). Acoustic startle, prepulse inhibition, locomotion, and latent inhibition in the neurolepticresponsive (NR) and neuroleptic-nonresponsive (NNR) lines of mice. Psychopharmacology (Berl) 139:322-331. (Pubitemid 28435029)
25. Konradi C, Heckers S (2001). Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 50:729-742. (Pubitemid 33086760)
26. Lanis A, Schmidt WJ (2001). NMDA receptor antagonists do not block the development of sensitization of catalepsy, but make its expression statedependent. Behav Pharmacol 12:143-149. (Pubitemid 32458126)
27. Li M, Davidson P, Budin R, Kapur S, Fleming AS (2004a). Effects of typical and atypical antipsychotic drugs on maternal behavior in postpartum female rats. Schizophr Res 70:69-80. (Pubitemid 38916630)
28. Li M, Parkes J, Fletcher PJ, Kapur S (2004b). Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacol Biochem Behav 78:811-819. (Pubitemid 39037744)
29. Li M, Fletcher PJ, Kapur S (2007). Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 32:263-272. (Pubitemid 46106933)
30. Li M, He W, Mead A (2009a). An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm. Behav Pharmacol 20:184-194.
31. Li M, He W, Mead A (2009b). Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus. Behav Pharmacol 20:84-98.
32. Li M, Sun T, Zhang C, Hu G (2010). Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning. Psychopharmacology (Berl) 212:45-57.
33. Li M, He E, Volf N (2011). Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment. Pharmacol Biochem Behav 98:559-569.
34. Mead A, Li M (2010). Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. J Psychopharmacol 24:1045-1053.
35. Meririnne E, Kankaanpaa A, Seppala T (2001). Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1-and D2-receptor antagonists. J Pharmacol Exp Ther 298:539-550. (Pubitemid 32673404)
36. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104. (Pubitemid 40139590)
37. Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE (1992). Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 89:4270-4274.
38. Paulson PE, Robinson TE (1995). Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse 19:56-65.
39. Pierce RC, Kalivas PW (1997). A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25:192-216. (Pubitemid 27501800)
40. Post RM, Contel NR, Gold P (1982). Impaired behavioral sensitization to cocaine in vasopressin deficient rats. Life Sci 31:2745-2750. (Pubitemid 13190747)
41. Rabin CR, Siegel SJ (2010). Antipsychotic dosing and drug delivery. Curr Top Behav Neurosci 4:141-177.
42. Remington G, Kapur S (2010). Antipsychotic dosing: how much but also how often? Schizophr Bull 36:900-903.
43. Richtand NM,Welge JA, Logue AD, Keck PE Jr., Strakowski SM, McNamara RK (2007). Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 32:1715-1726. (Pubitemid 47076385)
44. Robertson GS, Fibiger HC (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328.
45. Robertson GS, Matsumura H, Fibiger HC (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066. (Pubitemid 24377799)
46. Robinson TE (1984). Behavioral sensitization: characterization of enduring changes in rotational behavior produced by intermittent injections of amphetamine in male and female rats. Psychopharmacology (Berl) 84:466-475. (Pubitemid 15179663)
47. Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157-198. (Pubitemid 16100809)
48. Robinson TE, Becker JB, Presty SK (1982). Long-term facilitation of amphetamine-induced rotational behavior and striatal dopamine release produced by a single exposure to amphetamine: sex differences. Brain Res 253:231-241. (Pubitemid 13212235)
49. Robinson TE, Browman KE, Crombag HS, Badiani A (1998). Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neurosci Biobehav Rev 22:347-354. (Pubitemid 28194391)
50. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S (2007). 'Breakthrough' dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986. (Pubitemid 46438984)
51. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S (2008). Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 64:145-152.
52. Schmitt A,Weber S, Jatzko A, Braus DF, Henn FA (2004). Hippocampal volume and cell proliferation after acute and chronic clozapine or haloperidol treatment. J Neural Transm 111:91-100. (Pubitemid 38177820)
53. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, et al. (2006). Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51: 386-396. (Pubitemid 44061894)
54. Stewart RB, Gatto GJ, Lumeng L, Li TK, Murphy JM (1993). Comparison of alcohol-preferring (P) and nonpreferring (NP) rats on tests of anxiety and for the anxiolytic effects of ethanol. Alcohol 10:1-10. (Pubitemid 23062791)
55. Sun T, Hu G, Li M (2009). Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol 602:334-342.
56. Vanderschuren LJ, Kalivas PW (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 151:99-120. (Pubitemid 30646415)
57. Vanderschuren LJ, Schmidt ED, De Vries TJ, Van Moorsel CA, Tilders FJ, Schoffelmeer AN (1999). A single exposure to amphetamine is sufficient to induce long-term behavioral, neuroendocrine, and neurochemical sensitization in rats. J Neurosci 19:9579-9586. (Pubitemid 30228109)
58. Varvel SA, Vann RE, Wise LE, Philibin SD, Porter JH (2002). Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology (Berl) 160:182-191.
59. Vezina P (2004). Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci Biobehav Rev 27:827-839. (Pubitemid 38199613)
60. Vezina P (2007). Sensitization, drug addiction and psychopathology in animals and humans. Prog Neuropsychopharmacol Biol Psychiatry 31: 1553-1555. (Pubitemid 47625710)
61. Wadenberg ML, Hicks PB (1999). The conditioned avoidance response test reevaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862. (Pubitemid 29458891)
62. Zhang C, Li M (2012). Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine. Behav Pharmacol 23:66-79.